查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425071

经导管心臟瓣膜置换市场 - 2024 年至 2029 年预测

Transcatheter Heart Valve Replacement Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年经导管心臟瓣膜置换市值为54.95亿美元。

主动脉瓣狭窄可以透过经导管心臟瓣膜置换术进行手术治疗，其中涉及更换受损的主动脉瓣而不是将其切除。瓣膜置换术通常需要胸骨切开术或物理性打开胸部的心臟直视手术。 TAVI 是透过一个微小的孔进行的，使所有胸骨保持完整。也可能需要经导管主动脉瓣或经主动脉瓣植入来恢復瓣膜的循环功能。

经导管心臟瓣膜置换术市场扩大的机会

经导管主动脉瓣置换术(TAVR) 是一种微创技术，由于主动脉瓣狭窄(AS) 盛行率不断增加、老年人口不断增加以及对微创手术的总体需求不断增长，因此需求量很大。这些是经导管心臟瓣膜置换行业的重要驱动力。根据《心血管商业》报道，2021 年美国患者植入了 92,000 个 TAVR 瓣膜。由于疫情导致医疗业务整体下滑并影响医疗设备供应链，循环系统设备主要製造商收入大幅下降。

老年人口增加

推动经导管心臟瓣膜置换市场扩大的主要原因是人口老化，他们更容易罹患心臟病。在全球范围内，老年人的数量正在迅速增加。老龄化会增加心臟衰竭的风险，老年人更容易罹患这些疾病。随着人口老化增加这些疾病的盛行率，市场需求预计将增加并推动经导管心臟瓣膜置换市场的成长。

强化技术

经导管心臟瓣膜技术的发展取得了重大进展。这些发展正在创造更可靠、更安全、更容易植入的经导管心臟瓣膜产品。新型生物相容性和耐用材料的开发、使用 3D 列印来创建自订心臟瓣膜，以及成像和导航技术的进步（允许更精确地放置心臟瓣膜）正在导致经导管心臟瓣膜置换术。这些是其中的一些推动市场成长的技术进步。

经股动脉手术方法越来越受欢迎

经股动脉手术方法由于其微创手术、恢復时间短和降低医疗费用等优点，预计将在经导管心臟瓣膜置换术行业中占据主导地位。传统手术涉及使用少量麻醉剂透过股动脉植入人工瓣膜。同时，在经导管心臟瓣膜置换市场中，经心尖类别预计将大幅成长。经心尖方法的优点在于，它允许操作者在装置放置期间更容易地移动，并且由于主动脉瓣和左心室心尖附近而允许使用更大直径的鞘套。

到医院就诊的病人增加

随着越来越多的人去医院和诊所就诊，对心臟病的诊断和治疗的需求预计会增加，这将推动经导管心臟瓣膜置换市场在预测期内的成长。此外，工业创新持续改善前景。例如，为了扩大 AS 疾病患者的治疗选择，美国FDA 于 2021 年 9 月批准了 Abbott Laboratories, Inc. 的 Epic Plus 和 Epic Plus Supra 支架组织瓣膜。此外，主要製造商正在进行多个策略计划，这将有助于开拓经导管心臟瓣膜置换市场。

製造商优先开发二尖瓣产品。

由于主要製造商加大研究投入，心臟瓣膜置换术术中的经导管二尖瓣置换术（TMVR）正在成为该行业的新前沿。由于患者治疗需求未满足以及经导管心臟瓣膜置换行业解决方案的稀缺，多家製造商正在开发新的 TMVR 设备并形成战术性联盟。例如，2021 年 9 月，雅培的 EpicTM Plus 和 Epic Plus Supra 支架组织瓣膜获得美国食品药物管理局(FDA) 批准，扩大了主动脉或二尖瓣疾病患者的治疗选择。

欧洲经导管心臟瓣膜置换市场预计将迅速扩大。

在预测期内，预计人口中 AS 疾病和主动脉瓣瓣膜闭锁不全的盛行率将会增加，预计将推动欧洲市场的成长。经导管心臟瓣膜置换市场受到多个变数的影响，例如欧盟心臟瓣膜置换治疗的增加、经济成长、监管影响和新产品推出。例如，TAVR系统製造商Jena Valve Technology宣布将于2021年10月向欧洲推出其Trilogy心臟瓣膜系统。 Trilogy 在欧洲的正式商业首次亮相始于在德国多个中心进行的主动脉瓣瓣膜闭锁不全1 (AR) 和主动脉瓣狭窄 1 (AS) 手术。

市场扩大策略

医疗保健系统和保险公司提供更广泛的支付范围可能会推动患者接受 TAVR 的机会增加以及经导管心臟瓣膜置换市场的成长。然而，也有机会将中度风险和低危险群患者纳入 TAVR 适应症。目前，各个市场相关人员正在进行临床试验，以评估经导管心臟瓣膜置换术在各种患者类别中的有效性和安全性，这显着扩大了经导管心臟瓣膜置换术市场的潜力。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章经导管心臟瓣膜置换市场：副产品

  • 介绍
  • 经导管主动脉瓣置换术
  • 经导管二尖瓣修復与置换
  • 经导管肺动脉置换术

第六章经导管心臟瓣膜置换市场：透过手术方法

  • 介绍
  • 经股动脉路径
  • 经心尖入路
  • 其他的

第七章经导管心臟瓣膜置换市场：依最终用途分类

  • 介绍
  • 医院
  • 导管实验室

第八章经导管心臟瓣膜置换市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Medtronic
  • Meril Life
  • Edwards Lifesciences
  • Mayo Clinic
  • Abbott Vascular
  • Eternal Hospital
  • Jena Valve
  • Boston Scientific
  • Aetna
  • InnovHeart
简介目录
Product Code: KSI061616146

The transcatheter heart valve replacement market was valued at US$5.495 billion in 2022.

Aortic valve stenosis can be treated surgically using transcatheter heart valve replacement, which involves swapping out the damaged aortic valve instead of removing it. A sternotomy, or open-heart surgery when the chest is physically opened, is typically required for a valve replacement. The TAVI is carried out through microscopic holes, leaving all of the chest bones in place. Restoring the valve's circulatory system capabilities also entails implanting transcatheter aortic valves or transaortic valves.

Opportunities for the Transcatheter Heart Valve Replacement Market to increase

Transcatheter aortic valve replacement (TAVR) is a minimally invasive technique that is in high demand because of the increased prevalence of aortic valve stenosis (AS), the growing elderly population, and the rising need for less invasive procedures in general. These are some key drivers for the transcatheter heart valve replacement industry. In the United States, 92,000 TAVR valves were implanted in patients in 2021, according to Cardiovascular Business magazine. Major producers of cardiovascular equipment experienced significant revenue losses since the pandemic reduced the number of medical operations overall and affected the supply chain for medical devices.

Growing geriatric population

The key reason driving the expansion of the transcatheter heart valve replacement market is the ageing population, which is more prone to heart illness. Globally, the number of older individuals is rising quickly. Age increases a person's risk of heart failure, and older people are more likely to have these disorders. The market is projected to see increased demand due to the ageing population's increased prevalence of these diseases, which will propel the transcatheter heart valve replacement market growth.

Enhancement in Technology

Significant progress has been achieved in the creation of transcatheter heart valve technology. These developments have produced transcatheter heart valve products that are more dependable, secure, and simple to implant. The development of new biocompatible and long-lasting materials, the use of 3D printing to create custom heart valves, and the advancement of imaging and navigation technologies that enable more precise placement of the heart valve are some of the technological advancements that have fueled the transcatheter heart valve replacement market growth.

The transfemoral surgical approach is gaining popularity

The transfemoral surgical approach is anticipated to dominate the transcatheter heart valve replacement industry due to the advantages of minimally invasive surgery, quicker recovery periods, and reduced healthcare costs. The prosthetic valve is implanted through the femoral artery during the traditional operation using only a small amount of anaesthetic. On the other hand, the transcatheter heart valve replacement market is predicted to have significant growth in the transapical category. The transapical method is advantageous because it facilitates operator mobility during device installation and enables the use of sheaths with larger diameters because the aortic valve and left ventricular apex are nearby.

Increasing patient visits in hospitals

The need for heart disease diagnosis and treatment is anticipated to increase as more people visit hospitals and clinics, which will fuel the transcatheter heart valve replacement market growth throughout the projected period. Additionally, industrial innovation keeps improving prospects. For instance, to broaden the spectrum of therapeutic choices for patients with AS disease, the U.S. FDA authorised Abbott Laboratories, Inc.'s Epic Plus and Epic Plus Supra Stented Tissue Valves in September 2021. Additionally, important manufacturers take on several strategic projects that support the development of the transcatheter heart valve replacement market.

Manufacturers prioritise the creation of a mitral valve product.

Transcatheter mitral valve replacement (TMVR) in heart valve replacement is becoming a new frontier in the industry due to major manufacturers' growing investment in research. Patients' unmet treatment demands and the scarcity of solutions in the transcatheter heart valve replacement industry have prompted several producers to create new TMVR devices and form tactical alliances. For instance, in September 2021, The EpicTM Plus and Epic Plus Supra Stented Tissue Valves from Abbott were recently authorised by the U.S. Food and Drug Administration (FDA), expanding the range of treatment options for patients with aortic or mitral valve disease.

The market for transcatheter heart valve replacement in Europe is anticipated to expand quickly.

During the projection period, there is expected to be an increase in the prevalence of AS diseases and aortic regurgitation in the population, which will fuel Europe's market growth. The transcatheter heart valve replacement market is influenced by several variables, including an increase in heart valve replacement treatments, economic growth, regulatory repercussions, and new product introductions in the EU. For instance, JenaValve Technology, Inc., a producer of TAVR systems, announced the Trilogy heart valve system's introduction in Europe in October 2021. Trilogy's formal European commercial debut began with the operations, which comprised treating both aortic regurgitation1 (AR) and aortic stenosis1 (AS) in several centres around Germany.

Market Expansion Strategies

Increased patient access to TAVR and transcatheter heart valve replacement market growth may result from healthcare systems and insurance companies offering broader payment coverage. However, there is a chance to include intermediate and low-risk individuals in the TAVR indications. Clinical trials are now being conducted by various market players to assess the efficacy and safety of transcatheter heart valve replacement in various patient categories, which has the potential to considerably increase the transcatheter heart valve replacement market.

Market Key Developments

  • In December 2022, the newest generation transcatheter aortic valve implantation (TAVI) technology, Navitor, was made accessible by Abbott, a multinational healthcare business, for patients in India who have severe aortic stenosis and are at high or extremely high risk for surgery.
  • In September 2022, the FDA granted Edwards Lifesciences permission for its Sapien 3 transcatheter aortic valve, which is equipped with components that the firm says will form the basis of future heart valve implants.
  • In January 2022, a Hydra Transcatheter Aortic Heart Valve CE data study was published by Sahajanand Medical Technologies Limited in the American College of Cardiology's Cardiovascular Interventions publication.

Segmentation:

By Product

  • Transcatheter Aortic Valve Replacement
  • Transcatheter Mitral Valve Repair and Replacement
  • Transcatheter Pulmonary Valve Replacement

By Surgical Approach

  • Transfemoral Approach
  • Transapical Approach
  • Others

By End-Use

  • Hospitals
  • Cath Labs

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Transcatheter Aortic Valve Replacement
  • 5.3. Transcatheter Mitral Valve Repair and Replacement
  • 5.4. Transcatheter Pulmonary Valve Replacement

6. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY SURGICAL APPROACH

  • 6.1. Introduction
  • 6.2. Transfemoral Approach
  • 6.3. Transapical Approach
  • 6.4. Others

7. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY END-USE

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Cath Labs

8. TRANSCATHETER HEART VALVE REPLACEMENT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Medtronic
  • 10.2. Meril Life
  • 10.3. Edwards Lifesciences
  • 10.4. Mayo Clinic
  • 10.5. Abbott Vascular
  • 10.6. Eternal Hospital
  • 10.7. Jena Valve
  • 10.8. Boston Scientific
  • 10.9. Aetna
  • 10.10. InnovHeart